Evidence map›Paper›PMID 36556194›Full record

ArticleJournal of personalized medicine2022

Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient Population.

Kristine Ashcraft, Kendra Grande, Sara L Bristow, Nicolas Moyer, Tara Schmidlen, Chad Moretz, Jennifer A Wick, Burns C Blaxall

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A systematic review of real-world evidence on the clinical relevance, characterization, and utility ofJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025
    Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kristine AshcraftInvitae Corporation, 1400 16th Street, San Francisco, CA 94103, USA.ORCID 0000-0002-6609-0075
Kendra GrandeInvitae Corporation, 1400 16th Street, San Francisco, CA 94103, USA.
Sara L BristowInvitae Corporation, 1400 16th Street, San Francisco, CA 94103, USA.ORCID 0000-0002-1173-4718
Nicolas MoyerInvitae Corporation, 1400 16th Street, San Francisco, CA 94103, USA.ORCID 0000-0003-4269-2327
Tara SchmidlenInvitae Corporation, 1400 16th Street, San Francisco, CA 94103, USA.ORCID 0000-0002-9749-112X
Chad MoretzInvitae Corporation, 1400 16th Street, San Francisco, CA 94103, USA.
Jennifer A WickThe Christ Hospital Health Network, 2139 Auburn Avenue, Cincinnati, OH 45219, USA.ORCID 0000-0002-5160-6438
Burns C BlaxallThe Christ Hospital Health Network, 2139 Auburn Avenue, Cincinnati, OH 45219, USA.

Funding

Accreditation Foundation Committee, American College of Cardiology Quality Initiative
6 · The paper itself

Abstract

Utilizing pharmacogenomic (PGx) testing and integrating evidence-based guidance in drug therapy enables an improved treatment response and decreases the occurrence of adverse drug events. We conducted a retrospective analysis to validate the YouScript

Indexed as

adverse drug eventsmedication managementpharmacogeneticspharmacogenomicsphenoconversionpopulation healthprecision medicine

Identifiers

PMID36556194
PMCPMC9783707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.